Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
View/ Open
Date
2016-09-01Author
Sharp, A
Welti, J
Blagg, J
de Bono, JS
Type
Journal Article
Metadata
Show full item recordAbstract
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466.
Collections
Subject
Animals
Humans
Mice
Receptors, Androgen
Antineoplastic Agents
Alternative Splicing
Male
Protein Interaction Domains and Motifs
Molecular Targeted Therapy
Androgen Receptor Antagonists
Prostatic Neoplasms, Castration-Resistant
Research team
Medicinal Chemistry 1
Prostate Cancer Targeted Therapy Group
Translational Therapeutics
Language
eng
Date accepted
2016-05-26
License start date
2016-09
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 22 (17), pp. 4280 - 4282
Publisher
AMER ASSOC CANCER RESEARCH